GlassScriptPhysician profile
Leandro Petersen Moraes
NPI 1285078527
$1,085.01
in general payments reported to CMS, 2019-2025
27 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $293 · 2021: $433 · 2023: $19.43 · 2024: $32.86 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $159 · Education: $14.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $158.57 |
| Education | $14.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $173.42 | 2019-2025 | Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $85.40 | 2019-2024 | |
| Amgen INC. | $85.14 | 2019-2020 | |
| Celgene Corporation | $82.63 | 2021-2025 | Opdualag |
| Lilly USA, LLC | $73.08 | 2020-2021 | |
| Incyte Corporation | $51.90 | 2019-2021 | |
| Array Biopharma INC | $38.53 | 2021-2024 | Braftovi, Tukysa, Mektovi |
| Myovant Sciences INC. | $37.46 | 2021 | |
| Tempus Ai, INC | $35.69 | 2025 | Xt Cdx |
| Merck Sharp & Dohme LLC | $35.24 | 2019-2020 | |
| Gilead Sciences, INC. | $34.99 | 2021 | |
| Genentech USA, INC. | $32.67 | 2019-2020 | |
| Glaxosmithkline, LLC. | $31.01 | 2020 | |
| Emd Serono, INC. | $26.72 | 2019 | |
| Epizyme, INC. | $25.36 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $24.80 | 2019 | |
| Puma Biotechnology, INC. | $23.98 | 2021 | |
| Beigene USA, INC. | $23.07 | 2020 | |
| Genzyme Corporation | $21.29 | 2020 | |
| Aadi Bioscience, INC. | $20.19 | 2025 | Fyarro |
| Seagen INC. | $19.81 | 2021 | |
| Intuitive Surgical, INC. | $19.43 | 2023 | Da Vinci Surgical System |
| Sun Pharmaceutical Industries INC. | $19.24 | 2021 | |
| Foundation Medicine, INC. | $18.81 | 2021 | |
| Kite Pharma, INC. | $16.24 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.21 | 2021 | |
| Myriad Genetic Laboratories, INC. | $13.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leandro Moraes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.